Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma

Autor: Melhem Solh, Karin Havenith, Jay Feingold, Brad S. Kahl, Erin Reid, Luqiang Wang, Carmelo Carlo-Stella, Leonard T. Heffner, John Radford, Owen A. O'Connor, Paolo Caimi, William Townsend, Joseph Boni, Kirit M. Ardeshna, David Ungar, Yajuan Gu Qin, Mehdi Hamadani

Publikováno v: Blood
Hamadani, M, Radford, J, Carlo-Stella, C, Caimi, P F, Reid, E G, O'Connor, O A, Feingold, J, Ardeshna, K M, Townsend, W M, Solh, M, Heffner, L T, Ungar, D, Wang, L, Boni, J P, Havenith, K, Qin, Y G & Kahl, B 2021, ' Final Results of a Phase 1 Study of Loncastuximab Tesirine in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma ', Blood, vol. 137, no. 19, pp. 2634-2645 . https://doi.org/10.1182/blood.2020007512

The prognosis for patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) remains poor, with a need for alternatives to current salvage therapies. Loncastuximab tesirine (ADCT-402) is an antibody-drug conjugate comprising a hum

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::749b478dd36863d89191135470f4ddaa
https://doi.org/10.1182/blood.2020007512

Inhibition of IRF5 cellular activity with cell-penetrating peptides that target homodimerization.

Autor: Banga, Jaspreet¹, Srinivasan, Dinesh², Chia-Chi Sun³, Thompson, Cherrie D.¹, Milletti, Francesca⁴, Kuo-Sen Huang², Hamilton, Shannon², Su Song¹, Hoffman, Ann F.², Yajuan Gu Qin², Matta, Bharati¹, LaPan, Margaret¹, Qin Guo¹, Gang Lu², Dan Li¹, Hong Qian², Bolin, David R.², Liang, Lena², Wartchow, Charles², Jin Qiu³

Publikováno v: Science Advances. 5/15/2020, Vol. 6 Issue 20, p1-16. 16p.